Merck (MRK) said Thursday that its late-stage study evaluating winrevair against placebo in adults recently diagnosed with pulmonary arterial hypertension functional class II or III at intermediate or high risk of disease progression will be stopped early.
The company said the decision to stop the study was based on the positive results of the interim analysis of another late-stage trial known as Zenith, as well as review of all data from the winrevair clinical program to date.
Merck said findings from the study will be available later this year and presented at a future medical congress.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。